Sugi Predict

Sugi Predict / Compounds / SCHEMBL29625959

SCHEMBL29625959

SCHEMBL29625959

Nc1cccc(-c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 3/20 1.00
▸ CYP3A4 P08684 3/20 0.58
▸ CASP1 P29466 1/20 0.58
▸ RECQL P46063 1/20 0.58
▸ MAP4K4 O95819 2/20 0.58
▸ MEN1 O00255 3/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ LMNA P02545 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ HPGD P15428 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ CA12 O43570 1/20 0.57
▸ CA1 P00915 1/20 0.57
▸ CA2 P00918 1/20 0.57
▸ CA9 Q16790 1/20 0.57
▸ MECP2 P51608 1/20 0.57
▸ TAAR1 Q96RJ0 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL173011 1.00 MAOA (1.00) MAOACYP3A4CASP1RECQLMAP4K4
Hydrochloric Acid SCHEMBL7125902 0.97 MAOA (0.95) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL30469285 0.97 MAOA (0.95) MAOACYP3A4CASP1RECQLMAP4K4
Hydrogen Sulfide SCHEMBL28625051 0.97 MAOA (0.95) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL6797870 0.97 MAOA (0.95) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL29726707 0.97 MAOA (0.95) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL17306371 0.97 MAOA (0.95) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL29057846 0.97 MAOA (0.95) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL22104536 0.97 MAOA (0.95) MAOACYP3A4CASP1RECQLMAP4K4
Hydrochloric Acid SCHEMBL30114339 0.97 MAOA (0.95) MAOACYP3A4CASP1RECQLMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-01-14 — — US claimed
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS DONG A SOCIO HOLDINGS CO LTD (KR) 2023-01-05 — — US claimed
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS LILLY CO ELI (US) 2025-11-20 — — US disclosed
US-12404298-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2025-09-02 — — US disclosed
CN-120153496-A Binder comprising polyamide polymer, positive electrode for secondary battery comprising same, and secondary battery comprising same 韩松化学株式会社 2025-06-13 — — CN disclosed
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-01-14 — — US disclosed
WO-2024238574-A1 CDK INHIBITOR COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2024-11-21 — — WO disclosed
CN-118063462-A Matrine 14-site chiral derivative and preparation method and application thereof 广西大学 2024-05-24 — — CN disclosed
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-01-18 — — US disclosed
US-11787834-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2023-10-17 — — US disclosed
CN-116754697-A Enrichment method and detection method of aromatic amine compounds in environmental flue gas and preparation method of sulfonic acid group functionalized organic material 中国烟草总公司郑州烟草研究院 2023-09-15 — — CN disclosed
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS DONG A SOCIO HOLDINGS CO LTD (KR) 2023-01-05 — — US disclosed
CN-115326994-A Method and system for simultaneously analyzing multi-class smoke exposure biomarkers and using method 上海烟草集团有限责任公司 2022-11-11 — — CN disclosed
US-20220324904-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2022-10-13 — — US disclosed
WO-2022199289-A1 NOVEL ANDROGEN RECEPTOR DEGRADER, PREPARATION METHOD, AND MEDICAL USE 中国药科大学 2022-09-29 — — WO disclosed
WO-2022056087-A2 LOW-TEMPERATURE CASE HARDENING OF ADDITIVE MANUFACTURED ARTICLES AND MATERIALS AND TARGETED APPLICATION OF SURFACE MODIFICATION SWAGELOK COMPANY (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs MERTK, ERBB2, SRC MAOA 3302/4885CYP3A4 1547/4885CASP1 3870/4885
US-12404298-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R MAOA 3267/4885CYP3A4 911/4885CASP1 1809/4885
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R MAOA 3267/4885CYP3A4 911/4885CASP1 1809/4885
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R MAOA 3267/4885CYP3A4 911/4885CASP1 1809/4885
US-11787834-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R MAOA 3267/4885CYP3A4 911/4885CASP1 1809/4885
US-20220324904-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R MAOA 3267/4885CYP3A4 911/4885CASP1 1809/4885
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS MERTK, ERBB2, SRC MAOA 3302/4885CYP3A4 1547/4885CASP1 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.